YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.92 CNY | -0.20% |
|
-2.51% | +9.70% |
| May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
| May. 13 | Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch | MT |
| Sales 2024 * | 42.35B 5.85B | Sales 2025 * | 45.66B 6.3B | Capitalization | 96.21B 13.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.64B 640M | Net income 2025 * | 5.04B 696M | EV / Sales 2024 * | 1.88 x |
| Net cash position 2024 * | 16.43B 2.27B | Net cash position 2025 * | 14.58B 2.01B | EV / Sales 2025 * | 1.79 x |
| P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
19.2
x | Employees | 8,834 |
| Yield 2024 * |
3.64% | Yield 2025 * |
4.2% | Free-Float | 38.53% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.20% | ||
| 1 week | -2.51% | ||
| Current month | -5.82% | ||
| 1 month | -2.78% | ||
| 3 months | +8.47% | ||
| 6 months | +6.50% | ||
| Current year | +9.70% |
1 week
53.75
56.00
1 month
53.0158.00
Current year
44.8858.00
1 year
44.8858.00
3 years
44.8893.63
5 years
44.88116.63
10 years
33.64116.63
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Dong
CEO | Chief Executive Officer | 47 | 21-03-02 |
Jia Ma
DFI | Director of Finance/CFO | 47 | 22-05-31 |
Pin Yao Yin
COO | Chief Operating Officer | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Shan Xie
BRD | Director/Board Member | 49 | 22-11-06 |
Ying Xia He
BRD | Director/Board Member | 52 | 89-11-30 |
Hong Dong Lu
BRD | Director/Board Member | 58 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 2 M€ | -17.92% | - | |
| 1.32% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 53.92 | -0.20% | 6,165,036 |
| 24-05-23 | 54.03 | -0.88% | 7,859,458 |
| 24-05-22 | 54.51 | -1.25% | 7,591,260 |
| 24-05-21 | 55.2 | +0.36% | 9,530,736 |
| 24-05-20 | 55 | -0.56% | 10,918,480 |
End-of-day quote Shenzhen S.E., May 23, 2024
More quotes
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
53.92
CNY
Average target price
64.08
CNY
Spread / Average Target
+18.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.70% | 13.28B | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 000538 Stock
